Abstract Library

#3335 Efficacy of somatostatin analogue (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)

Introduction: Currently, there is minimal published data on the efficacy of SSAs for well-differentiated G3 NETs. Randomized trials have demonstrated a progression-free survival (PFS) benefit and limited response for lower grade 1-2 NETs, but the optimal therapy for metastatic G3 NETs is unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: McGarrah P

Authors: McGarrah P, Liu A, Hobday T, Starr J, Kendi A,

Keywords: somatostatin analogues, lanreotide, octreotide, well-differentiated grade 3 neuroendocrine tumor, G3net, G3nen,

#3283 Tumor growth rate in well-differentiated G1-3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Implications for clinical trials

Introduction: Drug development in G1-3 GEP-NETs is hampered by heterogeneous tumor biology and the cytostatic nature of most active agents. Optimal care of G3NETs is ill-defined, as recent phase 3 studies have not accounted for this group. Tumor growth rate (TGR) allows dynamic evaluation of growth and has prognostic value in G1-2; little is known about TGR in G3.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Wang S, Whitman J, Paciorek A, Le B, Zhang L,

Keywords: GEP-NET, tumor growth rate, Ki67,

#3256 Surgical outcomes in extrapulmonary G3 neuroendocrine neoplasms

Introduction: Incidence of high-grade neuroendocrine (NE) neoplasms (G3NENs) is increasing. Heterogeneity of these tumors (well-differentiated NE tumors, G3NETs; poorly differentiated NE carcinomas, NEC) presents obstacles to clinical management and role of surgery is uncertain. Majority of published data suggest benefit of surgery in NECs limited to localized disease. Role of surgery in G3NET remains ill-defined.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lopez M

Authors: Lopez M, Whitman J, Le B, Paciorek A, Zhang L,

Keywords: resection, G3NET, differentiation, G3NEN,

#3136 Prognosis and the role of Rb expression in metastatic grade 3 neuroendocrine carcinoma (G3NEC), results from the multicenter retrospective RbNEC study

Introduction: Rb has been suggested to be a predictive/prognostic factor in G3NEC in which platinum etoposide (PE) is the first line treatment whatever primary.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V,

Keywords: neuroendocrine carcinoma, g3, Rb, prognosis,

#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study

Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,